AstraZeneca and Daiichi Sankyo win EU tumour‑agnostic approval for Enhertu
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
AstraZeneca ( (GB:AZN) ) has issued an announcement.
AstraZeneca and Daiichi Sankyo have secured European Commission approval for Enhertu as the first tumour-agnostic HER2-directed therapy and antibody drug conjugate for adults with previously treated, unresectable or metastatic HER2-positive solid tumours lacking satisfactory options. The decision, based on Phase II DESTINY trials in multiple tumour types, broadens Enhertu’s EU label to six indications, underscores the growing role of biomarker-driven precision oncology, and triggers a $25 million milestone payment to Daiichi Sankyo, reinforcing both partners’ positioning in high-value cancer therapeutics and potentially expanding testing and treatment for HER2-positive disease across the region.
The most recent analyst rating on (GB:AZN) stock is a Buy
with a £180.00 price target.
To see the full list of analyst forecasts on AstraZeneca stock,
see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.
To see Spark’s full report on AZN stock,
click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on oncology, cardiovascular, renal and metabolic diseases, and respiratory disorders, while Daiichi Sankyo is a Japanese pharmaceutical group with a strong oncology pipeline. The two companies jointly develop and commercialise Enhertu, a HER2-directed antibody drug conjugate targeting patients with HER2-positive cancers across multiple tumour types.
Average Trading Volume: 2,169,745
Technical Sentiment Signal: Strong Buy
Current Market Cap: £222.1B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.
